secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001326732-25-000048
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days
-------------------------------------------------------------------------------

- XmAb942 well tolerated; no serious AEs, no discontinuations.
- Half-life >71 days supports 12-week maintenance dosing in planned Phase 2b UC study.
- Phase 2b XENITH-UC trial in moderate-to-severely active UC expected to start H2 2025 (n~220).
- TL1A x IL23p19 bispecific lead selection on track; FIH study planned for 2026.
- Company to host call at 5pm ET today.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/0001326732-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/xncr-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer